Individuals with T2D initiating SGLT-2i were compared with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i) using 1:1 propensity score matching to account for key confounders. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.